Beijing Tide Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 1995-05-29
- Employees
- -
- Market Cap
- -
- Website
- https://www.tidepharm.com
Clinical Trials
6
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
3 (50.0%)A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
Phase 1
Not yet recruiting
- Conditions
- Refractory Chronic Cough
- Interventions
- Drug: TCR1672 tablet
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06213363
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
Phase 1
Recruiting
- Conditions
- GVHD, Chronic
- Interventions
- Drug: TDI01 suspension
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT06169722
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis
Phase 2
Not yet recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: TDI01 suspension
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT06102083
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
Phase 1
Recruiting
- Conditions
- Patients with Advanced Solid Tumors
- Interventions
- Drug: TCC1727 tablet（1）Drug: TCC1727 tablet（2）
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT05970016
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery
Phase 2
Not yet recruiting
- Conditions
- Pain, Post-operative
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05950152
- Locations
- 🇨🇳
the Third XiangYa Medical Hospital of Central South University, Changsha, Hunan, China
- Prev
- 1
- 2
- Next
News
Beijing Tide's First-in-Class AT2R Antagonist TRD205 Enters Phase II Trials for Chronic Post-Surgical Pain
Beijing Tide Pharmaceutical has dosed the first patient in Phase II trials of TRD205, a first-in-class AT2R antagonist targeting chronic post-surgical neuropathic pain without opioid-related risks.